Diagnostics

A new bipartisan law injects vital funds into neuromuscular disease research, a victory driven by years of relentless patient advocacy. Here's what it means.

After a four-year campaign, the World Health Organization is poised to recognize a silent liver epidemic, setting the stage for a new global NCD strategy.

Quanterix has submitted a multi-biomarker blood test to the FDA, a move that could revolutionize early Alzheimer's diagnosis and patient care.

Industrial giant AMETEK acquires LKC Technologies, aiming to revolutionize eye care with portable diagnostic devices for early disease detection.

A new AI-powered blood test from CareDx shows promise in detecting cancer relapse weeks earlier, offering new hope for transplant patients.

Promega's new diagnostic for KEYTRUDA gains NMPA approval, opening doors for targeted solid tumor therapy amid China's growing precision medicine market.

National imaging giant RadNet has acquired Northwest Radiology's six centers, marking its entry into Indiana and signaling a major shift for the Midwest market.

Pharming Group projects strong 2026 growth, fueling ambitious clinical programs for rare immunodeficiencies and mitochondrial diseases.

A landmark Medicare decision doubles payment for contrast-enhanced ultrasound, positioning the safer, cheaper alternative to challenge CT and MRI dominance.

Death rates fall, but a new report reveals rising incidence and stark inequities. Can new drugs and AI reshape the future for all patients?

A new liquid biopsy more accurately predicts cancer recurrence than standard methods, offering new hope and clarity for patients after surgery.

Brainomix launches its award-winning stroke AI platform with novel Net Water Uptake tech, promising to improve diagnoses, treatment decisions, and patient outcomes.

Early clinical results for MP0712, a novel Radio-DARPin, suggest a breakthrough for targeting aggressive cancers like SCLC while sparing healthy tissue.

Promising Phase 2 data for a potential first-in-class neuropathic corneal pain therapy to be showcased, offering new hope for a debilitating condition.

After selling its proteomics arm to Illumina for $350M+, Standard BioTools is flush with cash but faces a pivotal moment to fix its core business.

With backing from a top hospital, VolitionRx seeks reimbursement for its Nu.Q® blood test, aiming to transform lung cancer care in France and beyond.

Known for non-opioid pain relief, Scilex is diversifying with a major investment in a stealthy diagnostic firm, hinting at a new data-driven strategy.

The global fitness giant is exploring a Wall Street listing and launching a DNA-based longevity program, signaling a major push for market leadership.

A landmark study validates Panakeia's AI, which provides critical cancer biomarker results in minutes, promising to revolutionize patient care globally.

A massive NHS trial in The Lancet shows AI-powered stethoscopes dramatically improve early detection of heart disease. Is this the future of primary care?